The clinical characteristics and prognosis of de novo acute myeloid leukemia patients with CCAAT/enhancer binding protein α mutations
10.3760/cma.j.issn.1009-9921.2015.05.005
- VernacularTitle:CCAAT/增强子结合蛋白α基因突变急性髓系白血病患者临床特征及预后
- Author:
Lu WANG
;
Long SU
;
Yehui TAN
;
Ruiping HU
;
Jiuwei CUI
;
Sujun GAO
;
Wei LI
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,acute;
CCAAT/enhancer binding protein α mutations;
Immunophenotype;
Prognoses
- From:
Journal of Leukemia & Lymphoma
2015;24(5):274-277,286
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical characteristics and prognosis of acute myeloid leukemia (AML) patients with CCAAT/enhancer binding protein α (CEBPA) mutations.Methods 208 patients with de novo AML were retrospectively analyzed with regard to frequency of CEBPA mutations,clinical characteristics,therapeutic response and long-term outcome.Results CEBPA mutations were detected in 37 patients (17.8 ％),with 29 cases of double mutations and 8 cases of single mutation.In 117 cases of patients with normal karyotype,28 cases (23.9 ％) were detected with CEBPA mutations.As compared with no CEBPA mutation,the following characteristics were observed in patients with CEBPA double mutations.Presented with younger age at diagnosis,82.8 ％ (24/29) of the patients were M1 and M2.Presented with higher peripheral white blood cell count,higher hemoglob in and low platelet count.And increases of CD7,CD34 and HLA-DR expression.Compared with those without mutation,patients with biCEBPA mutations had better overall survival (OS) (2-years OS:100 ％ vs 75.1％,P =0.045).Conclusion BiCEBPA mutation is one of the favorable prognosis indicators.
